3-(1H-咪唑-1-基)丙酸 | 18999-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(1H-咪唑-1-基)丙酸
• 中文别名: 3-(1H-咪唑-1-基）丙酸
• 英文名称: 4-(N-imidazolyl)propionic acid
• 英文别名: 3-(1H-imidazol-1-yl)propanoic acid；imidazolium propionate；3-(1H-imidazol-1-yl)propionic acid；1-(2-Carboxyethyl)imidazol；β-(1-Imidazolyl)propionsaeure；3-(imidazol-1-yl)-propionic acid；3-(1-imidazolyl)propionic acid；1-(2-Carboxymethyl)imidazol；Imidazolylpropionsaeure；4-(1H-imidazol-1-yl)propanoic acid；1H-imidazole-1-propionic acid；imidazolyl propionic acid；3-imidazol-1-ylpropanoic acid
• CAS: 18999-45-6
• 化学式: C₆H₈N₂O₂
• mdl: MFCD02731119
• 分子量: 140.142
• InChiKey: VSFNAZLYGOOSEY-UHFFFAOYSA-N

物化性质

• 熔点：
  147-149
• 沸点：
  390.9±25.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R37/38,R41
• 海关编码：
  2933290090
• 危险类别：
  IRRITANT
• WGK Germany：
  3
• 储存条件：
  室温且干燥

SDS

Name:	3-(1H-Imidazol-1-yl)propanoic acid Material Safety Data Sheet
Synonym:	none know
CAS:	18999-45-6

Section 1 - Chemical Product MSDS Name:3-(1H-Imidazol-1-yl)propanoic acid Material Safety Data Sheet
Synonym:none know

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18999-45-6	3-(1H-Imidazol-1-yl)propanoic acid	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

---

Section 7 - HANDLING and STORAGE
Handling:
Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 18999-45-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 147 - 149 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H8N2O2
Molecular Weight: 140.14

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases, amines.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18999-45-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(1H-Imidazol-1-yl)propanoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 18999-45-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 18999-45-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18999-45-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(1H-咪唑-1-基)丙酸 在 草酰氯 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 4-(N-imidazolyl)propionic acid chloride
  参考文献：
  名称：

  Synthesis and characterization of blocked and ligand-appended hemes derived from atropisomeric meso-diphenylporphyrins

  摘要：

  DOI：

  10.1021/ja00290a027
• 作为产物：
  描述：

  ethyl 3-(1H-imidazol-1-yl)propanoate 在 硫酸 作用下， 以 水 为溶剂， 反应 10.0h， 生成 3-(1H-咪唑-1-基)丙酸
  参考文献：
  名称：

  一种羧基咪唑类质子型离子液体及其制备方法与应用

  摘要：

  本发明涉及润滑油添加剂领域，具体为一种铵盐羧基咪唑质子型离子液体及其制备方法与应用。本发明的离子液体为铵盐羧基咪唑质子型离子液体，结构式如式(1)所示： 本发明铵盐羧基咪唑质子型离子液体制备方法简单，且不含卤素、硫、磷等元素，不会对环境造成污染；本发明中的铵盐羧基咪唑质子型离子液体作为添加剂在复合锂基润滑脂中的减摩抗磨性能优异。

  公开号：

  CN113979946A

文献信息

• [EN] INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF<br/>[FR] INHIBITEURS DE TRANSPORT DE CRÉATINE ET LEURS UTILISATIONS
  申请人：RGENIX INC

  公开号：WO2016176636A1

  公开（公告）日：2016-11-03

  This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

  这项发明涉及抑制肌酸转运和/或肌酸激酶的化合物，包括这些化合物的药物组合物，以及利用这些化合物和组合物治疗癌症的方法。
• [EN] CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CHDI INC

  公开号：WO2010011302A1

  公开（公告）日：2010-01-28

  Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。包括至少一种化学实体和一种或多种药用可接受载体的制药组合物。描述了治疗对KMO活性抑制敏感的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的有效量以减少疾病或疾病的症状的方法。这些疾病包括亨廷顿病等神经退行性疾病。治疗方法包括将至少一种化学实体作为单一活性剂或将至少一种化学实体与一种或多种其他治疗剂结合使用。还提供了筛选能够抑制KMO活性的化合物的方法。
• [EN] INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF<br/>[FR] INHIBITEURS DE TRANSPORT DE LA CRÉATINE ET LEURS UTILISATIONS
  申请人：RGENIX INC

  公开号：WO2015168465A1

  公开（公告）日：2015-11-05

  This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

  这项发明涉及抑制肌酸转运和/或肌酸激酶的化合物，包括这种化合物的药物组合物，以及利用这种化合物和组合物治疗癌症的方法。
• Imidazodiazepine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US05387585A1

  公开（公告）日：1995-02-07

  The novel imidazodiazepine derivatives of the formula: ##STR1## wherein the substituents are as described in the specification, can be used for the control or prevention of epileptic seizures, anxiety, tension and excitation states, sleep disorders, schizophrenic symptoms, hepatic encephalopathy and senile dementia, as well as, in the partial or complete antagonization of undesired side-effects of substances acting on benzodiazepine receptors after over-dosage or after their use in intensive medicine and in anesthesia.

  翻译结果如下： 所述的咪唑二氮䓬衍生物的公式为：##STR1##，其中取代基如说明书中所述，可用于控制或预防癫痫发作、焦虑、紧张和兴奋状态、睡眠障碍、精神分裂症症状、肝性脑病和老年痴呆症，以及部分或完全拮抗在过量使用或在其在重症医学和麻醉中使用后作用于苯二氮䓬受体的物质的副作用。
• Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor
  申请人：——

  公开号：US20030225097A1

  公开（公告）日：2003-12-04

  Compounds of formula (I): 1 wherein: X is a group of formula (A) or (B): 2 and R 1 , R 2 , R 3 , R 4 , n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being are also described.

  式(I)的化合物： 其中： X是式(A)或(B)的基团： 而R1、R2、R3、R4、n、x、y和z的定义如所述。 还描述了它们的制备过程以及它们在治疗由神经肽Y5受体介导的疾病中的用途，如在温血动物，如人类中的用途。